Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rohit Bakshi

Neurology Brookline, MA Medical Doctor

NPI 1598722274 CMS profile 253277

One Brookline Place, Partners Multiple Sclerosis Center, Brookline, MA 02445

Open in the dashboard

General payments

$196,200

191 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,440,164 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Rohit Bakshi of Brookline, MA is reported in the CMS Open Payments database as having received $196,200 across 191 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,440,164 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,860 32
2024 General $23,778 13
2023 General $35,414 24
2022 General $31,409 41
2021 General $31,186 29
2020 General $5,572 6
2019 General $27,980 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rohit Bakshi
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Rohit Bakshi were reported at $40,860. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Rohit Bakshi Neurology median Middle half National median
2019 $27,980 $474 $118–$2,177 $163
2020 $5,572 $367 $82–$2,309 $114
2021 $31,186 $438 $104–$2,547 $132
2022 $31,409 $442 $103–$2,388 $149
2023 $35,414 $464 $119–$2,312 $160
2024 $23,778 $468 $119–$2,323 $164
2025 $40,860 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. EMD Serono, Inc. $177,587 181 payments
  2. Genzyme Corporation $14,773 9 payments
  3. E.R. Squibb & Sons, L.L.C. $3,840 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $145,604 28 payments
  2. Travel and Lodging $26,465 100 payments
  3. Consulting Fee $19,350 4 payments
  4. Food and Beverage $4,667 57 payments
  5. Education $113 2 payments
Products named General payments · program years 2019–2025
  1. ZEPOSIA $3,840 1 payment
  2. Mavenclad $974 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

67

Median for Neurology: 833

Drug cost

$373,582

Median for Neurology: $202,670

Branded share of claims

64.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aubagio Teriflunomide Brand 15 $211,154
Vumerity Diroximel Fumarate Brand 16 $134,198
Fingolimod Fingolimod Hcl Brand 12 $19,006
Teriflunomide Generic 11 $9,117
Baclofen Generic 13 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$1,519

Medicare's payments for the services billed

Medicare patients

13

Average age 65

Services billed

18

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
COPD 0%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record